Prot# EMD20001: Prospective, Randomized, Dbl-Bld, Placebo-Controlled, Dose Ranging, Multi-Center Study of Safety & Efficacy of 3 Days Continuous Intravenous Infusion of GR270773 in Treatment of Suspected or Confirmed Gram-Negative Severe Sepsis in Adults

Project: Research project

Project Details

StatusFinished
Effective start/end date11/22/0411/30/06

Funding

  • GlaxoSmithKline plc (EMD20001)